TJ-L-1-H-3

N/A

Report date: 2026/05/15 20:01:45

Base Information

Drug NameTJ-L-1-H-3
Drug Alias NameTJ-L-1-H-3TJ-L1H3TJ L1H3TJL1H3
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionAnti-Programmed death-ligand 1CD276 antigen inhibitors
TargetsProgrammed death-ligand 1CD276 antigen
Therapy Area/IndicationsAutoimmune DiseasesNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesI-Mab Biopharma Hongkong Ltd
China Registration ClassN/A

Develop Information

Active CompaniesI-Mab Biopharma Hongkong Ltd
Inactive CompaniesN/A
Active IndicationsAutoimmune DiseasesNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A